Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Types of Cancer / Breast Cancer / Breast Cancer
Last Modified: August 19, 2008
![]()
Dear OncoLink "Ask The Experts,"
I was diagnosed with an invasive ductal breast cancer. I underwent a right mastectomy with sentinel node biopsy (which was negative at the time of surgery). My permanent biopsy report showed that out of 8 lymph nodes, one had a micrometastasis. I am currently undergoing chemo and will finish in July. I have had a consult from a radiation oncologist about the possibility of having radiation because of the micrometastasis. She stated I am right in the middle and there aren't any studies to show that radiation would benefit me. Are you aware of any studies on treating micrometastasis of a lymph node(s)?
![]()
Terry Styles, MD, Assistant Professor of Radiation Oncology at the University of Pennsylvania, responds:
As in many areas of cancer care, local treatment of breast cancer continues to evolve. Two areas that are under evaluation is the use of radiation after mastectomy and the evaluation of the lymph node region.
For many years, the standard of care in patients receiving a mastectomy was to also have a complete axillary dissection at the same time. These lymph nodes were examined under a microscope for visible involvement with cancer cells. Patients with more than 4 positive lymph nodes were found to benefit from the addition of radiation in terms of local control and survival. Not quite ten years ago, 2 large studies were published demonstrating a benefit for patients with only 1- 3 positive lymph nodes. Because these studies were done on patients outside the United States with slightly different surgery than is done here, it is not yet the standard of care to recommend radiation after mastectomy if only 1 to 3 nodes are involved. A randomized trial is currently underway to evaluate whether the benefit seen in Europe would also be seen here in our patients. Nonetheless, individual assessment is essential to determine the benefit of post-mastectomy radiotherapy.
The second area undergoing change is the process used to evaluate the involvement of the lymph nodes. The advent of sentinel lymph node evaluation for breast cancer and melanoma revealed that careful evaluation of the sentinel lymph node with special stains demonstrated the occasional presence of small clusters of cancer cells in the lymph nodes. These clusters may contain just a few cells visible only with specialized staining (immunohistochemistry), or up to 2 mm with traditional staining (H&E). It became clear that these represented special cases of metastatic disease to the lymph nodes and as such, it is possible that standard prognostic information and treatment recommendations may not be as applicable in these cases.
Given the uncertainty of benefit of treatment for 1 positive lymph node, and the uncertainty of whether a micrometatasis (either of a few cells on IHC or up to 2mm on H&E) is the same as our older definition of positive lymph nodes, it is hard for me to recommend post- mastectomy radiation in a patient with 1 of 8 lymph nodes with micrometastases. Until additional studies are completed, there are little data at this time to support treatment because of this single micrometastatic lesion. This, however, is only one reason for post-mastectomy radiation, and decisions regarding the benefit of therapy are best made by a radiation oncologist who is fully knowledgeable of the details of your case.
Dr. Metz talks about how caring for cancer patients has affected his life. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)


